Hansa Biopharma announces positive results from NICE-01 trial of next generation IgG-cleaving molecule, HNSA-5487: Lund, Sweden Tuesday, October 8, 2024, 11:00 Hrs [IST] Hansa Bio ...
Professor Qiang said himself that the significance of this study is twofold. Firstly, it reveals that excessive IgG antibodies are a driving factor in aging, and secondly, that IgG linked to aging ...
Importantly, HNSA-5487 demonstrated lower pre-treatment anti-drug antibody (ADA) levels and significantly reduced ADA responses when compared to imlifidase, confirming an attractive immunogenicity ...
The following is a summary of “Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2,” published in the September 2024 issue of ...